FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286490588> ?p ?o ?g. }

• W4286490588 endingPage "482" @default.
• W4286490588 startingPage "472" @default.
• W4286490588 abstract "The bombesin derivative RM2 is a GRPr antagonist with strong binding affinity to prostate cancer (PCa). In this study, the impact of [68Ga]Ga-RM2 positron emission tomography-computed tomography (PET-CT) for the detection of primary PCa was compared with that of [18F]FCH PET-CT and multiparametric magnetic resonance imaging (mpMRI).This phase I/II study was conducted in 30 biopsy-positive PCa subjects. The patients were stratified into high (10 patients), intermediate (10 patients), and low risk (10 patients) for extraglandular metastases as defined by National Comprehensive Cancer Network (NCCN) criteria (NCCN Clinical Practice Guidelines in Oncology, 2016). The prostate gland was classified in 12 anatomic segments for data analysis of the imaging modalities as well as histopathologic findings. The segment with the highest radiotracer uptake was defined as the index lesion. All cases were scheduled to undergo prostatectomy with pelvic lymph node (LN) dissection in intermediate- and high-risk patients. Intraprostatic and pelvic nodal [68Ga]Ga-RM2 and [18F]FCH PET-CT findings were correlated with mpMRI and histopathologic results.Of the 312 analyzed regions, 120 regions (4 to 8 lesions per patient) showed abnormal findings in the prostate gland. In a region-based analysis, overall sensitivity and specificity of [68Ga]Ga-RM2 PET-CT in the detection of primary tumor were 74% and 90%, respectively, while it was 60% and 80% for [18F]FCH PET-CT and 72% and 89% for mpMRI. Although the overall sensitivity of [68Ga]Ga-RM2 PET-CT was higher compared to that of [18F]FCH PET-CT and mpMRI, the statistical analysis showed only significant difference between [68Ga]Ga-RM2 PET-CT and [18F]FCH PET-CT in the intermediate-risk group (p = 0.01) and [68Ga]Ga-RM2 PET-CT and mpMRT in the high-risk group (p = 0.03). In the lesion-based analysis, there was no significant difference between SUVmax of [68Ga]Ga-RM2 and [18F]FCH PET-CT in the intraprostatic malignant lesions ([68Ga]Ga-RM2: mean SUVmax: 5.98 ± 4.13, median: 4.75; [18F]FCH: mean SUVmax: 6.08 ± 2.74, median: 5.5; p = 0.13).[68Ga]Ga-RM2 showed promising PET tracer for the detection of intraprostatic PCa in a cohort of patients with different risk stratifications. However, significant differences were only found between [68Ga]Ga-RM2 PET-CT and [18F]FCH PET-CT in the intermediate-risk group and [68Ga]Ga-RM2 PET-CT and mpMRT in the high-risk group. In addition, GRP-R-based imaging seems to play a complementary role to choline-based imaging for full characterization of PCa extent and biopsy guidance in low- and intermediate-metastatic-risk PCa patients and has the potential to discriminate them from those at higher risks.• [68Ga]Ga-RM2 is a promising PET tracer with a high detection rate for intraprostatic PCa especially in intermediate-risk prostate cancer patients. • GRPr-based imaging seems to play a complementary role to choline-based or PSMA-based PET/CT imaging in selected low- and intermediate-risk PCa patients for better characterization and eventually biopsy guidance of prostate cancer disease." @default.
• W4286490588 created "2022-07-22" @default.
• W4286490588 creator A5004652975 @default.
• W4286490588 creator A5021075936 @default.
• W4286490588 creator A5026147553 @default.
• W4286490588 creator A5043984769 @default.
• W4286490588 creator A5050153046 @default.
• W4286490588 creator A5051465639 @default.
• W4286490588 creator A5059197712 @default.
• W4286490588 creator A5059466134 @default.
• W4286490588 creator A5061131802 @default.
• W4286490588 creator A5062078332 @default.
• W4286490588 creator A5079977409 @default.
• W4286490588 creator A5090058320 @default.
• W4286490588 date "2022-07-21" @default.
• W4286490588 modified "2023-09-25" @default.
• W4286490588 title "Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study" @default.
• W4286490588 cites W1490266165 @default.
• W4286490588 cites W1951669519 @default.
• W4286490588 cites W1971005131 @default.
• W4286490588 cites W2009542561 @default.
• W4286490588 cites W2010902574 @default.
• W4286490588 cites W2026239858 @default.
• W4286490588 cites W2030042532 @default.
• W4286490588 cites W2055703903 @default.
• W4286490588 cites W2055842486 @default.
• W4286490588 cites W2085562053 @default.
• W4286490588 cites W2086232140 @default.
• W4286490588 cites W2098226918 @default.
• W4286490588 cites W2131970757 @default.
• W4286490588 cites W2143841075 @default.
• W4286490588 cites W2145661651 @default.
• W4286490588 cites W2155394376 @default.
• W4286490588 cites W2158025968 @default.
• W4286490588 cites W2159329546 @default.
• W4286490588 cites W2164051596 @default.
• W4286490588 cites W2252550361 @default.
• W4286490588 cites W2410782911 @default.
• W4286490588 cites W2415973042 @default.
• W4286490588 cites W244971556 @default.
• W4286490588 cites W2470255787 @default.
• W4286490588 cites W2510815041 @default.
• W4286490588 cites W2595559817 @default.
• W4286490588 cites W2744422865 @default.
• W4286490588 cites W2765188120 @default.
• W4286490588 cites W2797284144 @default.
• W4286490588 cites W2888457361 @default.
• W4286490588 cites W2894536640 @default.
• W4286490588 cites W2914433591 @default.
• W4286490588 cites W2948239425 @default.
• W4286490588 cites W3012827461 @default.
• W4286490588 doi "https://doi.org/10.1007/s00330-022-08982-2" @default.
• W4286490588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35864350" @default.
• W4286490588 hasPublicationYear "2022" @default.
• W4286490588 type Work @default.
• W4286490588 citedByCount "4" @default.
• W4286490588 countsByYear W42864905882023 @default.
• W4286490588 crossrefType "journal-article" @default.
• W4286490588 hasAuthorship W4286490588A5004652975 @default.
• W4286490588 hasAuthorship W4286490588A5021075936 @default.
• W4286490588 hasAuthorship W4286490588A5026147553 @default.
• W4286490588 hasAuthorship W4286490588A5043984769 @default.
• W4286490588 hasAuthorship W4286490588A5050153046 @default.
• W4286490588 hasAuthorship W4286490588A5051465639 @default.
• W4286490588 hasAuthorship W4286490588A5059197712 @default.
• W4286490588 hasAuthorship W4286490588A5059466134 @default.
• W4286490588 hasAuthorship W4286490588A5061131802 @default.
• W4286490588 hasAuthorship W4286490588A5062078332 @default.
• W4286490588 hasAuthorship W4286490588A5079977409 @default.
• W4286490588 hasAuthorship W4286490588A5090058320 @default.
• W4286490588 hasBestOaLocation W42864905881 @default.
• W4286490588 hasConcept C118552586 @default.
• W4286490588 hasConcept C121608353 @default.
• W4286490588 hasConcept C126322002 @default.
• W4286490588 hasConcept C126838900 @default.
• W4286490588 hasConcept C127077266 @default.
• W4286490588 hasConcept C143409427 @default.
• W4286490588 hasConcept C16568411 @default.
• W4286490588 hasConcept C2775842073 @default.
• W4286490588 hasConcept C2775934546 @default.
• W4286490588 hasConcept C2776235491 @default.
• W4286490588 hasConcept C2779889316 @default.
• W4286490588 hasConcept C2780192828 @default.
• W4286490588 hasConcept C2780849966 @default.
• W4286490588 hasConcept C2989005 @default.
• W4286490588 hasConcept C71924100 @default.
• W4286490588 hasConceptScore W4286490588C118552586 @default.
• W4286490588 hasConceptScore W4286490588C121608353 @default.
• W4286490588 hasConceptScore W4286490588C126322002 @default.
• W4286490588 hasConceptScore W4286490588C126838900 @default.
• W4286490588 hasConceptScore W4286490588C127077266 @default.
• W4286490588 hasConceptScore W4286490588C143409427 @default.
• W4286490588 hasConceptScore W4286490588C16568411 @default.
• W4286490588 hasConceptScore W4286490588C2775842073 @default.
• W4286490588 hasConceptScore W4286490588C2775934546 @default.
• W4286490588 hasConceptScore W4286490588C2776235491 @default.
• W4286490588 hasConceptScore W4286490588C2779889316 @default.
• W4286490588 hasConceptScore W4286490588C2780192828 @default.

• next